FBLG: Advancing Fibroblast Therapy on Multiple Fronts
FibroBiologics, Inc. (FBLG) has recently disclosed the potential for its fibroblast therapy platform to be extended to additional therapeutic...
95 Views
FBLG: Ready to Transition to Clinical-Stage Company
On February 24, 2026, FibroBiologics, Inc. (FBLG) announced financial results for 2025 and provided an operational update. The company has secured...
167 Views
FBLG: Diabetic Foot Ulcer Trial of CYWC628 to Initiate in 1Q26
On October 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the third quarter of 2025 and provided a business update. The...
428 Views
FBLG: Advancing Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies
On September 10, 2025, FibroBiologics, Inc. (FBLG) announced significant advancements in the company's Bone Marrow Organoid platform that could...
301 Views
FBLG: Closes Third Tranche of 5M
On July 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the second quarter of 2025 and provided a business update. The...
196 Views